Cory Kasimov: GILD’s Phase II study data may be early, but first signs speak to a well-tolerated treatment.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Did this $4 billion fund make the right call on these two soaring biotechs?
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed …
